Market cap
$3.6bn
Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.
Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.
We expect our revenue growth to increase if more payers make a positive coverage decision and as payers enter into contracts with us, which should enhance our revenue and cash collections. Finally, when we increase our list price, it will increase the cumulative amounts billed but not positively impact accrued revenue. Product Revenue Our product revenue consists primarily of international sales of the Prosigna breast cancer IVD and related diagnostic kits, and services. Financial Overview Revenue Through June 30, 2026, we derived the majority of our revenue as testing revenue from the sale of Decipher Prostate and Afirma tests, delivered primarily to physicians in the United States. …VERACYTE, INC., 10-Q, period ended 2026-06-30, filed 2026-07-31